GLP-1 analogue therapy for obesity in people from Asia
- PMID: 38330985
- DOI: 10.1016/S2213-8587(24)00031-7
GLP-1 analogue therapy for obesity in people from Asia
Conflict of interest statement
TM-MT is supported by research funding from the UK National Institute for Health and Care Research (NIHR), NIHR Imperial Biomedical Research Centre, JP Moulton Charitable Foundation, Leadiant Pharmaceuticals and Diabetes UK. TM-MT is a consultant for and shareholder in Zihipp Ltd, a company that develops gut hormone analogues of GLP-1, oxyntomodulin, GIP, and peptide YY for obesity and diabetes. BK is supported by the JP Moulton Charitable Foundation and Diabetes UK, and declares no competing interests.
Comment on
-
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)00388-1. Epub 2024 Feb 5. Lancet Diabetes Endocrinol. 2024. PMID: 38330988 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical